Aldeyra Therapeutics, Inc. - 8-K Filing

Aldeyra Therapeutics requests FDA transfer of ADX-2191 review jurisdiction and withdraws existing Special Protocol Assessment. (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $ALDX

Read the full article at SEC EDGAR

More Regulatory news